Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease

Numerous clinical trials of anti‐amyloid beta (Aβ) immunotherapy in Alzheimer's disease have been performed. None of these have provided convincing evidence for beneficial effects. Using traditional frequentist meta‐analysis, the conclusion is that there is absence of evidence for a therapeutic effect, with a point estimate effect size of 0.05 (95% confidence interval −0.00 to 0.10, P = .055). In addition, this non‐significant effect equates to...